Direct Answer • Key Takeaway
The Food and Drug Administration (Fda) Recently Approved Two New Treatments for Some Adult Patients with Acute Myeloid Leukemia (Aml): Enasidenib (Idhifa®), a Drug That Targets Aberrant Forms of the Idh2 Protein; and Liposomal Cytarabine-Daunorubicin Cpx-351 (Vyxeos™), a Two-Drug Chemotherapy Combination Encapsulated. ..
